



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
		(Use several sheets if necessary)	
Applicant: McSwiggen et al.		Filing Date: October 31, 2003	Group: 1632

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
JW	1.	03/070918	08/28/03	WO (McSwiggen et al.)				
JW	2.	03/099298	12/04/03	WO (Tuschi et al.)				
JW	3.	04/047872	06/10/04	WO (Kaemmerer)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

JW	4.	International Search Report for PCT/US2004/017630 mailed March 8, 2005
JW	5.	Nelson et al., "The mRNA of α -Synuclein is a Putative Microna (MIRNA) Target," Program No. 558.8. 2003 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, 2003 online
JW	6.	Sapru et al., "Small Interfering RNA (SIRNA) – Mediated Silencing of α -Synuclein Gene Expression," Program No. 297.9, 2003 Abstract Viewer/Itinerary Planner, Washington, DC: Society for Neuroscience, 2003 online

EXAMINER 	DATE CONSIDERED 5/23/05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-372
(400/137)

Serial No.

10/698,311



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

October 31, 2003

Group:

1632

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
JW	*	10/151,116	05/17/02	Matulic-Adamic et al.			
JW	*	10/201,394	08/13/01	Vargeese et al.			
JW	*	10/427,160	04/30/03	Vargeese et al.			
JW	*	2001/0007666	07/12/01	Hoffman et al.			
JW	*	2002/0130430	12/29/00	Caster			
	*	60/082,404	04/20/98	Thompson et al.	Cover sheet only		
JW	*	60/358,580	02/20/02	Beigelman et al.			
JW	*	60/363,124	03/11/02	Beigelman et al.			
JW	*	60/386,782	06/06/02	Beigelman et al.			
JW	*	60/393,796	07/03/02	Beigelman et al.			
JW	*	60/399,348	07/29/02	Beigelman et al.			
JW	*	60/402,996	08/13/02	Usman et al.			
JW	*	60/406,784	08/29/02	Beigelman et al.			
JW	*	60/408,378	09/05/02	Beigelman et al.			
JW	*	60/409,293	09/09/02	Beigelman et al.			

EXAMINER <i>James Wottele</i>	DATE CONSIDERED <i>5/27/05</i>
-------------------------------	--------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632

	*	60/440,129	01/15/03	Beigelman et al.			
--	---	------------	----------	------------------	--	--	--

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JW	*	5,138,045	08/11/92	Cook et al.			
JW	*	5,214,136	05/25/93	Lin et al.			
JW	*	5,334,711	08/02/94	Sproat			
JW	*	5,624,803	04/29/97	Noonberg et al.			
JW	*	5,627,053	05/06/97	Usman et al.			
JW	*	5,631,360	05/20/97	Usman et al.			
JW	*	5,670,633	09/23/97	Cook et al.			
JW	*	5,716,824	02/10/98	Beigelman et al.			
JW	*	5,792,847	08/11/98	Buhr et al.			
JW	*	5,804,683	09/08/98	Usman et al.			
JW	*	5,814,620	09/29/98	Robinson et al.			
JW	*	5,831,071	11/03/98	Usman et al.			
JW	*	5,854,038	12/29/98	Cech et al.			
JW	*	5,889,136	03/30/99	Scaringe et al.			

EXAMINER		DATE CONSIDERED	5/27/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: McSwiggen et al.	
(Use several sheets if necessary)		Filing Date: October 31, 2003	Group: 1632

JW	*	5,898,031	04/27/99	Crooke				
JW	*	5,902,880	05/11/99	Thompson et al.				
JW	*	5,998,203	12/07/99	Adamic et al.				
JW	*	6,001,311	12/14/99	Brennan				
JW	*	6,005,087	12/21/99	Cook et al.				
JW	*	6,008,400	12/28/99	Scaringe et al.				
JW	*	6,054,576	04/25/00	Bellon et al.				
JW	*	6,107,094	08/22/00	Crooke				
JW	*	6,111,086	08/29/00	Scaringe et al.				
JW	*	6,117,657	09/12/00	Usman et al.				
JW	*	6,146,886	11/14/00	Thompson et al.				
JW	*	6,153,737	11/28/00	Manoharan et al.				
JW	*	6,162,909	12/19/00	Bellon et al.				
JW	*	6,180,613	01/30/01	Kaplitt et al.				
JW	*	6,235,310	05/22/01	Wang et al.				
JW	*	6,235,886	05/22/01	Manoharan et al.				
JW	*	6,300,074	10/09/01	Gold				
JW	*	6,303,773	10/16/01	Bellon et al.				
JW	*	6,335,434	01/01/02	Guzaev et al.				

EXAMINER <i>Jonathan Wotterberg</i>	DATE CONSIDERED <i>5/27/05</i>
--	---------------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632

JW	*	6,353,098	03/05/02	Usman et al.			
JW	*	6,362,323	03/26/01	Usman et al.			
JW	*	6,395,713	05/28/02	Beigelman et al.			
JW	*	6,437,117	08/20/02	Usman et al.			
JW	*	6,447,796	09/10/02	Vook et al.			
JW	*	6,469,158	10/22/02	Usman et al.			
JW	*	6,476,205	11/05/02	Buhr et al.			
JW	*	6,506,559	06/14/03	Fire et al.			
JW	*	6,528,631	03/04/03	Cook et al.			
JW	*	6,586,524	07/01/03	Sagara et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
JW	1.	4037501		AU (Graham et al.)				
JW	2.	2,359,180	08/03/00	CA (Kreutzer et al.)				
	3.	1144623 B1	01/29/02	EP (Kreutzer et al.)	<u>Non English document</u>			
JW	4.	89/02439	03/23/89	WO (Arnold et al.)				

EXAMINER		DATE CONSIDERED	5/27/05
-----------------	---	------------------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-372
(400/137)

Serial No.

10/698,311

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

October 31, 2003

Group:

1632

JW	5.	90/14090	11/29/90	WO (Gillespie et al.)				
PW	6.	91/03162	03/21/91	WO (Rossi et al.)				
PW	7.	92/07065	04/30/92	WO (Eckstein et al.)				
JW	8.	93/15187	08/05/93	WO (Usman et al.)				
JW	9.	93/23569	11/25/93	WO (Draper et al.)				
JW	10.	94/01550	01/20/94	WO (Agrawal et al.)				
JW	11.	94/02595	02/03/94	WO (Sullivan et al.)				
JW	12.	95/06731	03/09/95	WO (Usman et al.)				
JW	13.	95/11910	05/04/95	WO (Dudycz et al.)				
JW	14.	96/10390	04/11/96	WO (Ansell et al.)				
JW	15.	96/10391	04/11/96	WO (Choi et al.)				
JW	16.	96/10392	04/11/96	WO (Holland et al.)				
JW	17.	96/18736	06/20/96	WO (Beigelman, et al.)				
JW	18.	97/26270	07/24/97	WO (Beigelman et al.)				
JW	19.	98/13526	04/02/98	WO (Woolf et al.)				
	20.	99/07409	02/18/99	WO (Deschamps Depaillette et al.)	Non-English Doc			
JW	21.	99/14226	03/25/99	WO (Wengel et al.)				
JW	22.	99/31262	06/24/99	WO (Barry et al.)				
JW	23.	99/32619	07/01/99	WO (Fire et al.)				

EXAMINER

James W. Stenberg

DATE CONSIDERED

5/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-372
(400/137)

Serial No.

10/698,311

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

October 31, 2003

Group:

1632

JW	24.	99/49029	09/30/99	WO (Graham et al.)					
JW	25.	99/53050	10/21/99	WO (Waterhouse et al.)					
JW	26.	99/54459	10/28/99	WO (Thompson et al.)					
JW	230.	99/61631	12/02/99	WO (Heifetz et al.)					
JW	27.	00/01846	01/13/00	WO (Plaetinck et al.)					
JW	28.	00/44895	08/03/00	WO (Kreutzer et al.)					
JW	29.	00/44914	08/03/00	WO (Li et al.)					
JW	30.	00/49035	08/24/00	WO (Jen Sheen)					
JW	31.	00/53722	09/14/00	WO (O'Hare and Normand)					
JW	32.	00/63364	10/26/00	WO (Pachuk et al.)					
JW	33.	00/66604	11/09/00	WO (Wengel et al.)					
JW	34.	01/04313	01/18/01	WO (Satishchandran et al.)					
JW	35.	01/29058	04/26/01	WO (Mello et al.)					
JW	36.	01/36646	05/25/01	WO (Zernicka-Goetz et al.)					
JW	37.	01/38551	05/31/01	WO (Grossniklaus)					
JW	38.	01/42443	06/14/01	WO (Churikov et al.)					
JW	39.	01/49844	07/12/01	WO (Driscoll et al.)					
JW	40.	01/53475	07/26/01	WO (Cogoni et al.)					
JW	41.	01/68836	09/20/01	WO (Beach et al.)					

EXAMINER

John Wollerberg

DATE CONSIDERED

8/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-372
(400/137)

Serial No.

10/698,311

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

October 31, 2003

Group:

1632

Sw	42.	01/70944	09/27/01	WO (Honer et al.)					
Sw	43.	01/70949	09/27/01	WO (Graham et al.)					
	44.	01/72774	10/04/01	WO (Deak et al.)					
	45.	01/75164	10/11/01	WO (Tuschi et al.)					
	46.	01/92513	12/06/01	WO (Arndt et al.)					
	47.	01/96584	12/20/01	WO (Mushegian et al.)					
	✓ 48.	02/22636	03/21/02	WO (Bennett et al.)					
	✓ 49.	02/38805	05/16/02	WO (Echeverri et al.)					
	✓ 50.	02/44321	06/06/02	WO (Tuschi et al.)					
	✓ 51.	02/55692	07/18/02	WO (Kreutzer et al.)					
	✓ 52.	02/55693	07/18/02	WO (Kreutzer et al.)					
	✓ 53.	PCT/US03/05028	02/20/03	WO (McSwiggen et al.)					
	✓ 54.	PCT/US03/05346	02/20/03	WO (McSwiggen et al.)					
	✓ 55.	03/046185	06/05/03	WO (Wang et al.)					
✓	56.	03/047518	06/12/03	WO (Wang et al.)					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


Sw	57.	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," Trends Cell Biol. 2:139-144 (1992)
----	-----	--

EXAMINER <i>John Wolke</i>	DATE CONSIDERED <i>5/31/05</i>
----------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Att. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 31, 2003	Group: 1632

EW	69.	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
	70.	Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)
	71.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	72.	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	73.	Bonifati et al., "Mutations in the <i>DJ-1</i> Gene Associated with Autosomal Recessive Early-Onset Parkinsonism," <i>Science</i> , doi:10.1126/science.1077209 (2002)
	74.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
	75.	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>Neurosurg. Focus</i> 3(5):Article 4 (1997)
	76.	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," <i>J Neurosurg</i> 88:734-742 (1998)
	77.	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)
✓	78.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
✓	79.	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)

EXAMINER 	DATE CONSIDERED 5/31/05
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

04-372
(400/137)

Serial No.

10/698,311.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

October 31, 2003

Group:

1632

80.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in Enzymology</u> 211:3-19 (1992)
81.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <u>Nucleic Acids Research</u> 20:4581-4589 (1992)
82.	Chiu and Rana, "siRNA function in RNAi: A chemical modification analysis," <u>RNA</u> , 9, 1034-1048 (2003)
83.	Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector <i>in vitro</i> ," <u>Bull. Korean Chem. Soc.</u> , 22, 46-52 (2001)
84.	Chowrira et al., " <i>In Vitro</i> and <i>In Vivo</i> Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <u>J. Biol. Chem.</u> 269:25856-25864 (1994)
85.	Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," <u>Neuroscience Letters</u> 257:135-138 (1998)
86.	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <u>J. Am. Chem. Soc.</u> 113:6324-6326 (1991)
87.	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <u>The Journ. of Biol. Chem.</u> 257:939-945 (1982)
88.	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal <i>versus</i> Subcutaneous Administration," <u>Clinical Cancer Research</u> 5:2330-2337 (1999)
89.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <u>Trends In Genetics</u> 12:510-515 (1996)
90.	d'Aldin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission <i>in vivo</i> ," <u>Molecular Brain Research</u> 55:151-164 (1998)

EXAMINER

Don Walsh


DATE CONSIDERED

5/31/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		04-372 (400/137)	10/698,311
		Applicant: McSwiggen et al.	
		Filing Date: October 31, 2003	Group: 1632


Sv	91.	Dawson et al., "Rare genetic mutations shed light on the pathogenesis of Parkinson disease," <i>The Journal of Clinical Investigation</i> , 111(2),145-151 (2003)
	92.	Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999)
	93.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)
	94.	Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," <i>Journal of Endocrinology</i> 157:169-175 (1998)
	95.	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
	96.	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
	97.	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
	98.	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	99.	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
	100.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
U	101.	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6743-6747 (1990)

EXAMINER 	DATE CONSIDERED 5/31/05
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632


Sw	102.	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999)
	103.	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and <i>In Vivo</i> , Using β -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <i>Antisense and Nucleic Acid Drug Dev.</i> 10:469-478 (2000)
	104.	Erbacher et al., "Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <i>The Journal of Gene Medicine</i> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
	105.	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> 113:4000-4002 (1991)
	106.	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	107.	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
	108.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	109.	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003)
	110.	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
	111.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993)
	112.	Ghimikar et al., "Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides," <i>Neuroscience Letters</i> 247:21-24 (1998)
V	113.	Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)

EXAMINER		DATE CONSIDERED	5/31/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 31, 2003	Group: 1632

SW	114.	Godbey et al., Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)
	115.	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)
	116.	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <i>Neuroscience</i> 76:1153-1158 (1997)
	117.	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <i>Bioconjugate Chem.</i> 10:1068-1074 (1999)
	118.	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <i>Gene Therapy</i> 4:45-54 (1997)
	119.	Groothuis and Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," <i>Journal of NeuroVirology</i> 3:387-400 (1997)
	120.	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," <i>Science</i> 297:2232-2237 (2002)
	121.	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999)
	122.	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
	123.	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)
	124.	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <i>Science</i> 287:820-825 (2000)
✓	125.	Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," <i>Current Opinion in Molecular Therapeutics</i> 1:336-343 (1999)

EXAMINER		DATE CONSIDERED	9/31/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632


126.	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," <i>Handbook of Exp. Pharmacol.</i> 137:165-192 (1999)
127.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <i>VCH</i> , 331-417
128.	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," <i>Science</i> 297:2056-2060 (2002)
129.	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the <i>let-7</i> Small Temporal RNA," <i>Science</i> 293:834-838 (2001)
130.	International Search Report for PCT/US03/05028, mailed October 17, 2003
131.	International Search Report for PCT/US03/05346, mailed October 17, 2003
132.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <i>Chem. Pharm. Bull.</i> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
133.	Iwata et al., " α -Synuclein Affects the MAPK Pathway and Accelerates Cell Death," <i>The Journal of Biological Chemistry</i> , 276(48), 45320-45329 (2001)
134.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <i>Science</i> 229:345-352 (1985)
135.	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <i>Tetrahedron Letters</i> 34:301-304 (1993) (sometimes mistakenly referred to as Jschke)
136.	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <i>Clinical Chemistry</i> 45:1628-1650 (1999)
137.	Jenuwein, "An RNA-Guided Pathway for the Epigenome," <i>Science</i> 297:2215-2218 (2002)
138.	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <i>Fundam. Clin. Pharmacol.</i> 13:16-26 (1999)

EXAMINER: <i>Sara Wolke</i>	DATE CONSIDERED <i>5/31/05</i>
-----------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 31, 2003	Group: 1632



Sw	139.	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA _A Receptor $\gamma 2$ Subunit," <u>Euro. Jour. of Pharmacology</u> 340:153-160 (1997)
	140.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
	141.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
	142.	Kunath et al., "The Structure of PEG-Modified Poy(Ethylene Imines) Influences Biodistribution and Pharmacokinetics of Their Complexes with NF- κ B Decoy in Mice," <u>Pharmaceutical Research</u> , 19, 810-817 (2002)
	143.	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <u>Reviews in Molecular Biotechnology</u> 74:27-38 (2000)
	144.	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <u>Chemical Reviews</u> 95:2601-2627 (1995)
	145.	Lasic and Papahadjopoulos, "Liposomes Revisited," <u>Science</u> 267:1275-1276 (1995)
	146.	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," <u>ACS Symposium Series</u> 752:184-192 (2000)
	147.	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," <u>Glyconjugates J.</u> 4:317-328 (1987)
	148.	Lee et al., "Cell cycle aberrations by α -synuclein over-expression and cyclin B immunoreactivity in Lewy bodies," <u>Neurobiology of Aging</u> , 24(5), 687-696 (2003)
	149.	Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," <u>Nature Biotechnology</u> 19:500-505 (2002)
U	150.	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <u>Biochemical and Biophysical Research Communications</u> , 295, 744-748 (2002)

EXAMINER		DATE CONSIDERED	5/31/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632



Lw	151.	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <u>EMBO J.</u> 11:4411-4418 (1992)
	152.	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <u>Methods Enzymol.</u> 217:47-66 (1993)
	153.	Limbach et al., "Summary: the modified nucleosides of RNA," <u>Nucleic Acids Research</u> 22(12):2183-2196 (1994)
	154.	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <u>J. Am. Chem. Soc.</u> 120:8531-8532 (1998)
	155.	Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <u>Biochemical and Biophysical Research Communications</u> , 281, 639-644 (2001)
	231.	Lin et al., "Policing rogue genes," <u>Nature</u> , 402, 128-129 (1999)
	156.	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 90:8000-8004 (1993)
	157.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <u>J. Biol. Chem.</u> 270(42):24864-24870 (1995)
	158.	Loakes, "The Applications of Universal DNA Base Analogues," <u>Nucleic Acids Research</u> 29:2437-2447 (2001)
	159.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	160.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	161.	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <u>Cell</u> 110:563-574 (2002)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632



SW	162.	Masliah et al., "Dopaminergic Loss and Inclusion Body Formation in α -synuclein Mice: Implications for Neurodegenerative Disorders," <i>Science</i> , 287, 165-1269 (2000)
	163.	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
	164.	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides & Nucleotides</i> 10:287-290 (1991)
	165.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:399-403 (1986)
	166.	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," <i>RNA</i> 8:842-850 (2002)
	167.	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," <i>American Chemical Society</i> , pp. 24-39 (1994)
	168.	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," <i>Nature Biotechnology</i> 19:497-500 (2002)
	169.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <i>Science</i> 256:992-996 (1992)
	170.	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <i>Nucleic Acids Research</i> 22(14):2830-2836 (1994)
	171.	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <i>Nature Medicine</i> 1-6 (2002)
	172.	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> 107:309-321 (2001)
	173.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992)
✓	174.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632


Jw	175.	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995)
	176.	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991)
	177.	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001)
	178.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
	179.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)
	180.	Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," <i>Nature Biotechnology</i> 20:505-508 (2002)
	181.	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
	182.	Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System," <i>Bioconjugate Chem.</i> , 13, 845-854 (2002)
	183.	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
	184.	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," <i>J. Med. Chem.</i> 24:1388-1395 (1981)
V	185.	Rajakumar et al., "Effects of Intrastriatal Infusion of D ₂ Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:	
(Use several sheets if necessary)		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632


Sw	186.	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <u>Science</u> 297:1831 (2002)
	187.	Reinhart et al., "MicroRNAs in Plants," <u>Genes & Development</u> 16:1616-1626 (2002)
	188.	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <u>J. Am. Chem. Soc.</u> 113:5109-5111 (1991)
	189.	Roses, Allen D., "Apolipoprotein E and Alzheimer's Disease: The Tip of the Susceptibility Iceberg," <u>Annals of the New York Academy of Sciences</u> , 855:738-743 (1998)
	190.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
	191.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
	192.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
	193.	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <u>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</u> 23:941-949 (1999) [sometimes cited by RPI as <i>Prog Neuropsychopharmacol Biol Psychiatry</i> 23:941-949, 1999]
	194.	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <u>Molecular Cell</u> 10:537-548 (2002)
	195.	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)
	196.	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <u>Cancer and Metastasis Reviews</u> 12:303-324 (1993)
	197.	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <u>Nucleic Acids Research</u> 19:4247-4251 (1991)
✓	232.	Sharp et al., "RNAi and double-strand RNA," <u>Genes & Development</u> , 13:139-141 (1999)

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632

198.	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003)
199.	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense & Nucleic Acid Drug Development</i> 8:75-85 (1998)
233.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <i>Molecular Biology</i> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <i>Science</i>]
200.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)
201.	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc.," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)
202.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991)
203.	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <i>PNAS</i> , 99, 14640-14645 (2002)
204.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
205.	Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> Volume LII, pp. 123-133 (1987)
206.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
207.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
208.	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13:3191-3197 (1999)

EXAMINER		DATE CONSIDERED	5/31/05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 31, 2003	Group: 1632

Lw	209.	Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001)
	210.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	211.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
	212.	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Reviews</i> 90:544-584 (1990)
	213.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <i>TIBS</i> 17:334-339 (1992)
	214.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <i>J. Am. Chem. Soc.</i> 109:7845-7854 (1987)
	215.	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <i>Nucleic Acids Symposium Series</i> 31:163-164 (1994)
	216.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <i>Nucleic Acids Research</i> 21:3249-3255 (1993)
	217.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <i>Annu. Rev. Biochem.</i> 67:99-134 (1998)
	218.	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <i>Science</i> 297:1833-1837 (2002)
	234.	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <i>Proc. Natl. Acad. Sci. USA</i> , 95, 13959-13964 (1998)

EXAMINER	Lous Wolla	DATE CONSIDERED	5/31/05
----------	------------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-372 (400/137)	Serial No. 10/698,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		October 31, 2003	1632

fsw	219.	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <u>Journal of Virology</u> 65:5531-5534 (1994)
/	220.	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)
/	221.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
/	222.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
/	223.	Wu and Wu, "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <u>The Journ. of Biol. Chem.</u> 262:4429-4432 (1987)
/	224.	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," <u>BioPharm</u> 32-38 (1999)
/	225.	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," <u>Nature Biology, Published online: 29 June 2003, doi:10.1038/nbt843</u> (August 2003 Volume 21 Number 8 pp 885-890) (2003)
/	226.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 (1993)
/	227.	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)
/	228.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
V	229.	Dawson et al., "Molecular Pathways of Nuerodegeneration in Parkinson's Disease," <u>Science</u> , Vol. 302, October 31, 2003

EXAMINER	Lout Wolb	DATE CONSIDERED	5/31/05
----------	-----------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.